GlassScriptPhysician profile
Anthony Aemmer
NPI 1659974806
$9,290.16
in general payments reported to CMS, 2019-2025
23 companies · $3,014 in 2025
The $3,014 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $1,649 · 2023: $1,416 · 2024: $2,560 · 2025: $3,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,701 · Education: $174 · Consulting Fee: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,701.09 |
| Education | $174.16 |
| Consulting Fee | $115.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,120.95 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,504.21 | 2021-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $853.36 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $753.39 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $663.84 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $631.30 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $604.41 | 2021-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $427.63 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $376.24 | 2022-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Axsome Therapeutics, INC. | $264.77 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $212.23 | 2022-2025 | Trintellix |
| Indivior INC. | $150.07 | 2022-2025 | Perseris, Sublocade |
| Vanda Pharmaceuticals INC. | $145.88 | 2022-2025 | Fanapt, Hetlioz |
| Janssen Scientific Affairs, LLC | $115.00 | 2024 | Spravato |
| Sunovion Pharmaceuticals INC. | $113.24 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $107.57 | 2022-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $102.48 | 2023-2025 | Qelbree, Qelbree |
| Allergan, INC. | $29.99 | 2021 | |
| Exact Sciences Corporation | $26.71 | 2024 | Cologuard Collection Kit |
| Tris Pharma INC | $24.01 | 2025 | Dyanavel Xr |
| Eisai INC. | $24.00 | 2021 | |
| Novo Nordisk INC | $21.78 | 2025 | Ozempic, Rybelsus |
| Noven Therapeutics, LLC | $17.10 | 2025 | Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Aemmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.